Bacterial flagellin is a dominant antigen in Crohn disease

Chronic intestinal inflammation, as seen in inflammatory bowel disease (IBD), results from an aberrant and poorly understood mucosal immune response to the microbiota of the gastrointestinal tract in genetically susceptible individuals. Here we used serological expression cloning to identify commens...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of clinical investigation Vol. 113; no. 9; pp. 1296 - 1306
Main Authors Lodes, Michael J, Cong, Yingzi, Elson, Charles O, Mohamath, Raodoh, Landers, Carol J, Targan, Stephan R, Fort, Madeline, Hershberg, Robert M
Format Journal Article
LanguageEnglish
Published United States American Society for Clinical Investigation 01.05.2004
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Chronic intestinal inflammation, as seen in inflammatory bowel disease (IBD), results from an aberrant and poorly understood mucosal immune response to the microbiota of the gastrointestinal tract in genetically susceptible individuals. Here we used serological expression cloning to identify commensal bacterial proteins that could contribute to the pathogenesis of IBD. The dominant antigens identified were flagellins, molecules known to activate innate immunity via Toll-like receptor 5 (TLR5), and critical targets of the acquired immune system in host defense. Multiple strains of colitic mice had elevated serum anti-flagellin IgG2a responses and Th1 T cell responses to flagellin. In addition, flagellin-specific CD4(+) T cells induced severe colitis when adoptively transferred into naive SCID mice. Serum IgG to these flagellins, but not to the dissimilar Salmonella muenchen flagellin, was elevated in patients with Crohn disease, but not in patients with ulcerative colitis or in controls. These results identify flagellins as a class of immunodominant antigens that stimulate pathogenic intestinal immune reactions in genetically diverse hosts and suggest new avenues for the diagnosis and antigen-directed therapy of patients with IBD.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Address correspondence to: Robert M. Hershberg, Dendreon Corporation, 3005 First Avenue, Seattle, Washington 98121, USA. Phone: (206) 829-1625; Fax: (206) 256-4540; E-mail: rhershberg@dendreon.com.
ISSN:0021-9738
1558-8238
DOI:10.1172/jci200420295